Definition and Overview
Diabetic autonomic neuropathy (DAN) is one of the common chronic complications of diabetes, caused by chronic hyperglycemia and resulting metabolic abnormalities that progressively damage autonomic nerve fibers [2]. Since the autonomic nervous system regulates involuntary bodily functions including cardiovascular, gastrointestinal, urogenital, sudomotor, and pupillary responses, damage produces diverse symptoms throughout the body.
Diabetic autonomic neuropathy develops in approximately 20-40% of diabetic patients, with incidence increasing with longer diabetes duration [2]. In type 1 diabetes patients, approximately 50% show autonomic dysfunction after 25 or more years of disease duration. The risk increases with poorer glycemic control, and each 1% increase in glycated hemoglobin (HbA1c) significantly raises the risk of autonomic neuropathy.
Classification
Diabetic autonomic neuropathy is classified according to the affected organ system as follows.
Cardiac autonomic neuropathy (CAN) is the most clinically significant form. Heart rate regulation impairment, exercise intolerance, and orthostatic hypotension occur, with increased risk of silent myocardial infarction and sudden death [1]. Gastrointestinal autonomic neuropathy includes gastroparesis, esophageal motility disorders, diabetic diarrhea, constipation, and fecal incontinence. Urogenital autonomic neuropathy includes bladder dysfunction (neurogenic bladder), male erectile dysfunction, female sexual dysfunction, and retrograde ejaculation. Sudomotor dysfunction manifests as distal anhidrosis and compensatory proximal hyperhidrosis. Pupillary abnormalities include impaired pupil dilation in dark environments and dark adaptation impairment.
Pathogenesis
Chronic hyperglycemia damages autonomic nerve fibers through multiple pathways [2].
Polyol pathway activation leads to sorbitol and fructose accumulation, causing osmotic stress within nerve cells. Accumulation of advanced glycation end products (AGEs) directly damages neural tissue and vasculature. Increased oxidative stress leads to mitochondrial dysfunction and nerve cell apoptosis. Decreased neurotrophic factors (nerve growth factor, NGF) impair the maintenance and regeneration capacity of autonomic nerve fibers. Endoneurial vasculature damage reduces blood supply to nerves, causing ischemic injury.
Since small-diameter unmyelinated autonomic nerve fibers (C fibers) are damaged before large-diameter myelinated fibers, an asymptomatic stage exists early on that can only be detected through heart rate variability testing.
Cardiac Autonomic Neuropathy
Cardiac autonomic neuropathy is the most clinically significant form of diabetic autonomic neuropathy. Research indicates that diabetic patients with cardiac autonomic neuropathy have an approximately 3.5-fold higher 5-year mortality rate compared to those without [4].
In the early stage, resting tachycardia (heart rate >100 beats/min) appears. This occurs because parasympathetic nerve damage precedes sympathetic damage, reducing the parasympathetic inhibitory effect on heart rate. Heart rate variability testing reveals decreased heart rate variation with the respiratory cycle (R-R interval variability) [1].
As the disease progresses, sympathetic nerves are also damaged, blunting the normal increase in heart rate and blood pressure during exercise. Silent myocardial infarction may occur, sometimes first discovered through ECG abnormalities or cardiac dysfunction without chest pain [1].
Orthostatic hypotension (systolic blood pressure decrease ≥20 mmHg or diastolic decrease ≥10 mmHg upon standing) results from impaired sympathetic vasoconstriction response. Orthostatic hypotension is reported in approximately 6-32% of diabetic patients [2].
Other Autonomic Involvement
Gastrointestinal Autonomic Neuropathy
Gastroparesis occurs in approximately 5-12% of diabetic patients [5]. Delayed gastric emptying causes postprandial fullness, nausea, vomiting, and abdominal bloating. It becomes a factor that makes glycemic control even more difficult. Diagnosis is made by gastric scintigraphy.
Common diabetic intestinal motility disorders include constipation (occurring in approximately 60% of diabetic patients) and nocturnal diarrhea (occurring in approximately 20%) [5].
Urogenital Autonomic Neuropathy
Bladder dysfunction is reported in approximately 43-87% of diabetic patients with neurogenic bladder [2]. Decreased bladder sensation causes overdistension, and reduced detrusor contractility leads to post-void residual urine and recurrent urinary tract infections.
Sudomotor Abnormalities
Distal anhidrosis (primarily feet and legs) and compensatory proximal hyperhidrosis (primarily trunk) are characteristic. Gustatory sweating -- excessive facial and neck sweating after meals -- can also occur in diabetic autonomic neuropathy.
Diagnosis
The American Diabetes Association (ADA) guidelines recommend the following five tests using heart rate variability as the standard evaluation method [2].
Deep breathing HRV: Measures the maximum-minimum heart rate difference during 6 deep breaths per minute. Valsalva maneuver test: Measures heart rate changes during forced expiration. Standing test (30:15 ratio): Measures the ratio of heart rates at the 30th and 15th beats after standing. Blood pressure response to standing: Confirms orthostatic hypotension. Blood pressure response to sustained handgrip: Evaluates blood pressure response to isometric exercise.
If abnormalities are confirmed in three or more of these tests, a diagnosis of clinically confirmed cardiac autonomic neuropathy is made [2].
Treatment
Glycemic control is the most fundamental treatment for prevention and progression suppression. In type 1 diabetes, intensive glycemic control has been confirmed in randomized controlled trials to reduce the incidence of cardiac autonomic neuropathy by approximately 53% [2].
For orthostatic hypotension, non-pharmacological measures (compression stockings, adequate fluid intake, increased salt intake, head-of-bed elevation) are applied first, with fludrocortisone or midodrine used when necessary. For gastroparesis, prokinetic agents such as metoclopramide and domperidone are used. PDE-5 inhibitors are effective for erectile dysfunction.